## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.6% in mid entry zone (3.0-6.0%), top quartile (81st pct) cross-sectional ranking. Short-term MRS_5 (3.1%) confirms momentum alignment. Strong momentum (+5.1% 5-day acceleration).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($90.39)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. State Street Corp Reduces Stock Position in Nasdaq, Inc. $NDAQ**
- Source: MarketBeat | 20251211T122037 | Somewhat-Bullish | Relevance: 100%
- State Street Corp recently decreased its stake in Nasdaq, Inc. by 0.6% during the second quarter, now holding 18,214,844 shares valued at over $1.6 billion. While State Street reduced its position, other hedge funds like Cary Street Partners Investment Advisory LLC and Leavell Investment Management Inc. increased their holdings in Nasdaq. Despite the reduction from State Street, institutional investors and hedge funds collectively own a significant 72.47% of Nasdaq's stock, and analysts maintain a "Moderate Buy" rating with a consensus price target of $101.00.

**2. Analysts Conflicted on These Financial Names: Figure Technology Solutions, Inc. Class A (FIGR) and Nasdaq (NDAQ)**
- Source: The Globe and Mail | 20251211T140746 | Somewhat-Bullish | Relevance: 100%
- Analysts have provided conflicting ratings for two financial sector companies: Figure Technology Solutions, Inc. Class A (FIGR) and Nasdaq (NDAQ). A Bank of America Securities analyst maintained a Hold rating on FIGR, while another analyst from the same firm issued a Buy rating for NDAQ. The consensus among analysts indicates a Moderate Buy for FIGR with a 24.3% upside and a Strong Buy for NDAQ with a 19.8% upside.

**3. Nasdaq Verafin Joins Global Anti-Scam Alliance**
- Source: ACCESS Newswire | 20251210T140947 | Bullish | Relevance: 97%
- Nasdaq Verafin has joined the Global Anti-Scam Alliance (GASA) as a Foundation Member, strengthening global efforts against scams, financial crime, and digital fraud. This partnership will extend to GASA's Brazil and Mexico chapters, leveraging Nasdaq Verafin's expertise in financial crime management technology to develop innovative defense strategies. The collaboration aims to enhance trust, transparency, and resilience in financial ecosystems, especially in vulnerable regions like Mexico and Brazil.

**4. Annual Changes to the Nasdaq-100 Index®**
- Source: The Globe and Mail | 20251213T015952 | Neutral | Relevance: 83%
- Nasdaq announced the annual reconstitution of the Nasdaq-100 Index®, effective December 22, 2025. Six companies will be added, including Alnylam Pharmaceuticals and Western Digital Corp., while six others, such as Biogen Inc. and Lululemon Athletica Inc., will be removed. The Nasdaq-100 Index tracks 100 of the largest non-financial companies on the Nasdaq Stock Market and underpins over 200 tracking products with more than $600 billion in assets under management.

**5. NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE**
- Source: Financial Times | 20251215T135719 | Somewhat-Bullish | Relevance: 75%
- The NYSE provides a daily pre-market update, noting that stocks are fractionally higher to start a busy economic data week. Seven of the top 10 IPOs in 2025 debuted on the NYSE, and NYSE President Lynn Martin highlighted maintaining momentum and simplifying the path for companies to go public as a 2026 priority. Baron Capital launched new active ETFs, and Dr. Martin Makary discussed modernizing FDA processes for drug development.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $114 | $109 | +5% |
| 2025-11-20 | Morgan Stanley | $110 | $97 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | main | Overweight |
| 2025-11-20 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($2.76M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +5.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 24.5x stretched relative to 11% growth. Quality metrics strong (margin 20%). Analyst sentiment positive (2 raises, avg +9%). Insider selling cluster ($2.8M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $53.7B |
| Beta | 1.02 |
| 52W Range | $64.84 - $97.63 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 24.5 |
| Current P/E | 27.3 |
| YoY Growth | 11.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.5% to 4.6% (+5.1% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 81st percentile. MRS_5 at 3.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.54), confirming momentum. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.57% (CS: 81) | Strong |
| RSI_14 | 67.8 | Neutral |
| MACD Histogram | 0.54 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.091x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $93.57
- **Stop Loss:** $90.39 (3.4% risk)
- **Target:** $98.34 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 377
- **Position Value:** $35,275.89
- **Portfolio %:** 35.28%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*